Reduced hippocampal insulin-degrading enzyme in late-onset Alzheimer's disease is associated with the apolipoprotein E-ε4 allele

David G. Cook, James B. Leverenz, Pamela J. McMillan, J. Jacob Kulstad, Sasha Ericksen, Richard A. Roth, Gerard D. Schellenberg, Lee-Way Jin, Kristina S. Kovacina, Suzanne Craft

Research output: Contribution to journalArticle

245 Citations (Scopus)

Abstract

Aβ is the major component of amyloid plaques characterizing Alzheimer's disease (AD). Aβ accumulation can be affected by numerous factors including increased rates of production and/or impaired clearance. Insulin-degrading enzyme (IDE) has been implicated as a candidate enzyme responsible for the degradation and clearance of Aβ in the brain. We have previously shown that AD patients exhibit abnormalities in insulin metabolism that are associated with apoliprotein E (APOE) status. The possible association of IDE with AD, as well as the link between APOE status and insulin metabolism, led us to examine the expression of IDE in AD. We report that hippocampal IDE protein is reduced by approximately 50% in ε4+ AD patients compared to ε4- patients and controls. The allele-specific decrease of IDE in ε4+ AD patients is not associated with neuronal loss since neuron-specific enolase levels were comparable between the AD groups, regardless of APOE status. Hippocampal IDE mRNA levels were also reduced in AD patients with the ε4 allele compared to AD and normal subjects without the ε4 allele. These findings show that reduced IDE expression is associated with a significant risk factor for AD and suggest that IDE may interact with APOE status to affect Aβ metabolism.

Original languageEnglish (US)
Pages (from-to)313-319
Number of pages7
JournalAmerican Journal of Pathology
Volume162
Issue number1
StatePublished - Jan 1 2003
Externally publishedYes

Fingerprint

Insulysin
Apolipoprotein E4
Alzheimer Disease
Alleles
Insulin
Phosphopyruvate Hydratase
Amyloid Plaques
Messenger RNA

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Cook, D. G., Leverenz, J. B., McMillan, P. J., Kulstad, J. J., Ericksen, S., Roth, R. A., ... Craft, S. (2003). Reduced hippocampal insulin-degrading enzyme in late-onset Alzheimer's disease is associated with the apolipoprotein E-ε4 allele. American Journal of Pathology, 162(1), 313-319.

Reduced hippocampal insulin-degrading enzyme in late-onset Alzheimer's disease is associated with the apolipoprotein E-ε4 allele. / Cook, David G.; Leverenz, James B.; McMillan, Pamela J.; Kulstad, J. Jacob; Ericksen, Sasha; Roth, Richard A.; Schellenberg, Gerard D.; Jin, Lee-Way; Kovacina, Kristina S.; Craft, Suzanne.

In: American Journal of Pathology, Vol. 162, No. 1, 01.01.2003, p. 313-319.

Research output: Contribution to journalArticle

Cook, DG, Leverenz, JB, McMillan, PJ, Kulstad, JJ, Ericksen, S, Roth, RA, Schellenberg, GD, Jin, L-W, Kovacina, KS & Craft, S 2003, 'Reduced hippocampal insulin-degrading enzyme in late-onset Alzheimer's disease is associated with the apolipoprotein E-ε4 allele', American Journal of Pathology, vol. 162, no. 1, pp. 313-319.
Cook, David G. ; Leverenz, James B. ; McMillan, Pamela J. ; Kulstad, J. Jacob ; Ericksen, Sasha ; Roth, Richard A. ; Schellenberg, Gerard D. ; Jin, Lee-Way ; Kovacina, Kristina S. ; Craft, Suzanne. / Reduced hippocampal insulin-degrading enzyme in late-onset Alzheimer's disease is associated with the apolipoprotein E-ε4 allele. In: American Journal of Pathology. 2003 ; Vol. 162, No. 1. pp. 313-319.
@article{acd3d39504ad4a9dbb64f51431344dbf,
title = "Reduced hippocampal insulin-degrading enzyme in late-onset Alzheimer's disease is associated with the apolipoprotein E-ε4 allele",
abstract = "Aβ is the major component of amyloid plaques characterizing Alzheimer's disease (AD). Aβ accumulation can be affected by numerous factors including increased rates of production and/or impaired clearance. Insulin-degrading enzyme (IDE) has been implicated as a candidate enzyme responsible for the degradation and clearance of Aβ in the brain. We have previously shown that AD patients exhibit abnormalities in insulin metabolism that are associated with apoliprotein E (APOE) status. The possible association of IDE with AD, as well as the link between APOE status and insulin metabolism, led us to examine the expression of IDE in AD. We report that hippocampal IDE protein is reduced by approximately 50{\%} in ε4+ AD patients compared to ε4- patients and controls. The allele-specific decrease of IDE in ε4+ AD patients is not associated with neuronal loss since neuron-specific enolase levels were comparable between the AD groups, regardless of APOE status. Hippocampal IDE mRNA levels were also reduced in AD patients with the ε4 allele compared to AD and normal subjects without the ε4 allele. These findings show that reduced IDE expression is associated with a significant risk factor for AD and suggest that IDE may interact with APOE status to affect Aβ metabolism.",
author = "Cook, {David G.} and Leverenz, {James B.} and McMillan, {Pamela J.} and Kulstad, {J. Jacob} and Sasha Ericksen and Roth, {Richard A.} and Schellenberg, {Gerard D.} and Lee-Way Jin and Kovacina, {Kristina S.} and Suzanne Craft",
year = "2003",
month = "1",
day = "1",
language = "English (US)",
volume = "162",
pages = "313--319",
journal = "American Journal of Pathology",
issn = "0002-9440",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Reduced hippocampal insulin-degrading enzyme in late-onset Alzheimer's disease is associated with the apolipoprotein E-ε4 allele

AU - Cook, David G.

AU - Leverenz, James B.

AU - McMillan, Pamela J.

AU - Kulstad, J. Jacob

AU - Ericksen, Sasha

AU - Roth, Richard A.

AU - Schellenberg, Gerard D.

AU - Jin, Lee-Way

AU - Kovacina, Kristina S.

AU - Craft, Suzanne

PY - 2003/1/1

Y1 - 2003/1/1

N2 - Aβ is the major component of amyloid plaques characterizing Alzheimer's disease (AD). Aβ accumulation can be affected by numerous factors including increased rates of production and/or impaired clearance. Insulin-degrading enzyme (IDE) has been implicated as a candidate enzyme responsible for the degradation and clearance of Aβ in the brain. We have previously shown that AD patients exhibit abnormalities in insulin metabolism that are associated with apoliprotein E (APOE) status. The possible association of IDE with AD, as well as the link between APOE status and insulin metabolism, led us to examine the expression of IDE in AD. We report that hippocampal IDE protein is reduced by approximately 50% in ε4+ AD patients compared to ε4- patients and controls. The allele-specific decrease of IDE in ε4+ AD patients is not associated with neuronal loss since neuron-specific enolase levels were comparable between the AD groups, regardless of APOE status. Hippocampal IDE mRNA levels were also reduced in AD patients with the ε4 allele compared to AD and normal subjects without the ε4 allele. These findings show that reduced IDE expression is associated with a significant risk factor for AD and suggest that IDE may interact with APOE status to affect Aβ metabolism.

AB - Aβ is the major component of amyloid plaques characterizing Alzheimer's disease (AD). Aβ accumulation can be affected by numerous factors including increased rates of production and/or impaired clearance. Insulin-degrading enzyme (IDE) has been implicated as a candidate enzyme responsible for the degradation and clearance of Aβ in the brain. We have previously shown that AD patients exhibit abnormalities in insulin metabolism that are associated with apoliprotein E (APOE) status. The possible association of IDE with AD, as well as the link between APOE status and insulin metabolism, led us to examine the expression of IDE in AD. We report that hippocampal IDE protein is reduced by approximately 50% in ε4+ AD patients compared to ε4- patients and controls. The allele-specific decrease of IDE in ε4+ AD patients is not associated with neuronal loss since neuron-specific enolase levels were comparable between the AD groups, regardless of APOE status. Hippocampal IDE mRNA levels were also reduced in AD patients with the ε4 allele compared to AD and normal subjects without the ε4 allele. These findings show that reduced IDE expression is associated with a significant risk factor for AD and suggest that IDE may interact with APOE status to affect Aβ metabolism.

UR - http://www.scopus.com/inward/record.url?scp=0037219221&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037219221&partnerID=8YFLogxK

M3 - Article

VL - 162

SP - 313

EP - 319

JO - American Journal of Pathology

JF - American Journal of Pathology

SN - 0002-9440

IS - 1

ER -